US 2010/0248359 A1Published application

Anti-Glypican 3 Antibody

AssigneeChugai Seiyaku Kabushiki Kaisha

InventorsKiyotaka Nakano, Takeshi Yoshino, Jun-Ichi Nezu, Hiroyuki Tsunoda, Tomoyuki Igawa, Hiroko Konishi, Megumi Tanaka, Izumi Sugo, Shigeto Kawai, Takahiro Ishiguro, Yasuko Kinoshita

Life of this patent

Estimating the term…

patentgrep

Loading patent…

Abstract

An antibody capable of binding to a specific region of glypican 3, as well as a humanized antibody created based on that antibody are disclosed. The anti-GPC3 antibody of the invention has a higher ADCC activity and CDC activity compared with those of a conventional antibody. The antibody of the present invention is useful as a cell growth inhibitor, an anticancer agent and an agent for diagnosis of cancers.

Claims17

Dependent claims

An isolated polynucleotide comprising a sequence that encodes an antibody heavy chain variable region of any one of (1)-(7):

(1) a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO:
84;
(2) a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO:
85;
(3) a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO:
86;
(4) a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO:
87;
(5) a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO:
88;
(6) a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO:
89;
or
(7) a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO:
90.

12 more elements

An isolated polynucleotide comprising a sequence that encodes an antibody light chain variable region of any one of (1)-(16) below:

(1) a light chain variable region having CDRs 1, 2 and 3 comprising the amino acid sequence set forth in SEQ ID NO:
143, 144 and 158, respectively
(2) a light chain variable region having CDRs 1, 2 and 3 comprising the amino acid sequence set forth in SEQ ID NO:
174, 144 and 158, respectively;
(3) a light chain variable region having CDRs 1, 2 and 3 comprising the amino acid sequence set forth in SEQ ID NO:
175, 144 and 158, respectively;
(4) a light chain variable region having CDRs 1, 2 and 3 comprising the amino acid sequence set forth in SEQ ID NO:
176, 144 and 158, respectively;
(5) a light chain variable region having CDRs 1, 2 and 3 comprising the amino acid sequence set forth in SEQ ID NO:
177, 144 and 158, respectively;
(6) a light chain variable region having CDRs 1, 2 and 3 comprising the amino acid sequence set forth in SEQ ID NO:
178, 144 and 158, respectively;
(7) a light chain variable region having CDRs 1, 2 and 3 comprising the amino acid sequence set forth in SEQ ID NO:
179, 144 and 158, respectively;
(8) a light chain variable region having CDRs 1, 2 and 3 comprising the amino acid sequence set forth in SEQ ID NO:
180, 144 and 158, respectively;
(9) a light chain variable region having CDRs 1, 2 and 3 comprising the amino acid sequence set forth in SEQ ID NO:
181, 144 and 158, respectively;
(10) a light chain variable region having CDRs 1, 2 and 3 comprising the amino acid sequence set forth in SEQ ID NO:
182, 144 and 158, respectively;
(11) a light chain variable region having CDRs 1, 2 and 3 comprising the amino acid sequence set forth in SEQ ID NO:
183, 144 and 158, respectively;
(12) a light chain variable region having CDRs 1, 2 and 3 comprising the amino acid sequence set forth in SEQ ID NO:
184, 144 and 158, respectively;
(13) a light chain variable region having CDRs 1, 2 and 3 comprising the amino acid sequence set forth in SEQ ID NO:
185, 144, and 158, respectively;
(14) a light chain variable region having CDRs 1, 2 and 3 comprising the amino acid sequence set forth in SEQ ID NO:
186, 144 and 158, respectively;
(15) a light chain variable region having CDRs 1, 2 and 3 comprising the amino acid sequence set forth in SEQ ID NO:
187, 144 and 158, respectively;
and
(16) a light chain variable region having CDRs 1, 2 and 3 comprising the amino acid sequence set forth in SEQ ID NO:
188, 144 and 158, respectively.

30 more elements

Dependencies are inferred from the claim text.

Facts

Application: 12/797,349Filed 9 Jun 2010
Priority: JP 2004-2036379 Jul 2004
Published: 30 Sep 2010
Term ends: Not estimatedThe source records don’t support an estimate.

Classification16 codes

A61P 1/00
Drugs for disorders of the alimentary tract or the digestive system
C07K 16/28
Against material from animals or humans: against receptors, cell surface antigens or cell surface determinants
A61P 1/16
Drugs for disorders of the alimentary tract or the digestive system: for liver or gallbladder disorders, e.g. hepatoprotective agents,…
A61P 35/00
Antineoplastic agents

Family

Application10/583,795Division · filed 21 Jun 2006
Application12/797,349Division
US 2007/0190599 A1Published application
US 7,776,329 B2Related patent
US 7,919,086 B2Related patent
US 2010/0248359 A1This patent

From the US filing history. Foreign family members aren’t listed.